WO2001038360A3 - Novel hcv non-structural polypeptide - Google Patents

Novel hcv non-structural polypeptide Download PDF

Info

Publication number
WO2001038360A3
WO2001038360A3 PCT/US2000/032326 US0032326W WO0138360A3 WO 2001038360 A3 WO2001038360 A3 WO 2001038360A3 US 0032326 W US0032326 W US 0032326W WO 0138360 A3 WO0138360 A3 WO 0138360A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
structural polypeptide
hcv non
polynucleotides
novel hcv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/032326
Other languages
French (fr)
Other versions
WO2001038360A2 (en
WO2001038360A9 (en
Inventor
Doris Coit
Angelica Medina-Selby
Mark Selby
Michael Houghton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22607625&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2001038360(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU25746/01A priority Critical patent/AU2574601A/en
Priority to CA2390082A priority patent/CA2390082C/en
Priority to EP00989206A priority patent/EP1233982B1/en
Priority to KR1020027006693A priority patent/KR100788812B1/en
Priority to JP2001540123A priority patent/JP2003516732A/en
Application filed by Chiron Corp filed Critical Chiron Corp
Priority to DE60036881T priority patent/DE60036881T2/en
Publication of WO2001038360A2 publication Critical patent/WO2001038360A2/en
Publication of WO2001038360A3 publication Critical patent/WO2001038360A3/en
Anticipated expiration legal-status Critical
Publication of WO2001038360A9 publication Critical patent/WO2001038360A9/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Polypeptides comprising a mutant non-structural Hepatitis C virus useful in diagnostic and/or immunogenic compositions are disclosed, in which the mutant is an N-terminal mutation that functionally disrupt the catalytic domain of NS3. Polynucleotides encoding these polypeptides, host cells transformed with polynucleotides and methods of using the polypeptides and polynucleotides are also disclosed.
PCT/US2000/032326 1999-11-24 2000-11-22 Novel hcv non-structural polypeptide Ceased WO2001038360A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DE60036881T DE60036881T2 (en) 1999-11-24 2000-11-22 NEW NON-STRUCTURAL HCV POLYPEPTIDE
CA2390082A CA2390082C (en) 1999-11-24 2000-11-22 Novel hcv non-structural polypeptide
EP00989206A EP1233982B1 (en) 1999-11-24 2000-11-22 Novel hcv non-structural polypeptide
KR1020027006693A KR100788812B1 (en) 1999-11-24 2000-11-22 Novel HCV Nonstructural Polypeptides
JP2001540123A JP2003516732A (en) 1999-11-24 2000-11-22 Novel HCV non-structural polypeptide
AU25746/01A AU2574601A (en) 1999-11-24 2000-11-22 Novel hcv non-structural polypeptide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16750299P 1999-11-24 1999-11-24
US60/167,502 1999-11-24

Publications (3)

Publication Number Publication Date
WO2001038360A2 WO2001038360A2 (en) 2001-05-31
WO2001038360A3 true WO2001038360A3 (en) 2002-03-07
WO2001038360A9 WO2001038360A9 (en) 2002-12-12

Family

ID=22607625

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/032326 Ceased WO2001038360A2 (en) 1999-11-24 2000-11-22 Novel hcv non-structural polypeptide

Country Status (9)

Country Link
EP (1) EP1233982B1 (en)
JP (1) JP2003516732A (en)
KR (1) KR100788812B1 (en)
CN (2) CN101684146A (en)
AT (1) ATE376558T1 (en)
AU (1) AU2574601A (en)
CA (1) CA2390082C (en)
DE (1) DE60036881T2 (en)
WO (1) WO2001038360A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491808B2 (en) 2000-06-15 2009-02-17 Novartis Vaccines And Diagnostics, Inc. HCV non-structural protein mutants and uses thereof
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
AU2001292151B2 (en) * 2000-08-17 2006-05-04 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6858590B2 (en) 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
CN1880457B (en) 2001-10-11 2010-05-26 麦克公司 Ad6 recombinant nucleic acid
ATE467680T1 (en) 2001-10-11 2010-05-15 Merck Sharp & Dohme HEPATITIS C VIRUS VACCINE
CN1678630A (en) * 2002-07-02 2005-10-05 希龙公司 HCV fusion proteins with modified NS3 domains
CA2957200C (en) 2002-10-16 2020-05-26 Gen-Probe Incorporated Compositions and methods for detecting west nile virus
US7927840B2 (en) 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine
CA2566725A1 (en) * 2004-05-17 2005-12-01 Chiron Corporation Truncated hepatitis c virus ns5 domain and fusion proteins comprising same
ATE542140T1 (en) * 2004-08-27 2012-02-15 Novartis Vaccines & Diagnostic NON-STRUCTURAL HCV PROTEIN MUTANTS AND POSSIBLE USES THEREOF
EP2460533A3 (en) * 2004-10-18 2014-01-08 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
JP5475279B2 (en) 2005-06-17 2014-04-16 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ Hepatitis C virus nucleic acid vaccine
WO2008024518A2 (en) * 2006-08-25 2008-02-28 Novartis Ag Hcv fusion polypeptides
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
WO2010112733A1 (en) * 2009-03-30 2010-10-07 bioMérieux Solid support for the detection of hcv
CN102645534B (en) * 2012-04-26 2015-08-12 杭州市萧山区第一人民医院 Based on the method for quantum point coding microball chip detection hepatitis C virus
CN105378099B (en) 2013-03-14 2021-05-11 雅培制药有限公司 HCV core lipid binding domain monoclonal antibodies
EP2970947A4 (en) * 2013-03-14 2016-10-12 Abbott Lab Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection
JP6505076B2 (en) 2013-03-14 2019-04-24 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ HCV antigen-antibody combination assay and methods and compositions for use therein

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0450931A1 (en) * 1990-04-04 1991-10-09 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
WO1993009253A1 (en) * 1991-11-07 1993-05-13 Baxter Diagnostics Inc. Epitope mapping ot the c33c region of hcv
WO1995025122A1 (en) * 1994-03-17 1995-09-21 The Scripps Research Institute Peptides for inducing cytotoxic t lymphocyte responses to hepatitis c virus
EP0696640A2 (en) * 1994-08-12 1996-02-14 Boehringer Mannheim Gmbh Recombinant antigen from the NS3 region of hepatitis C virus
US5683864A (en) * 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
WO1999038880A1 (en) * 1998-01-30 1999-08-05 The General Hospital Corporation Genetic immunization with nonstructural proteins of hepatitis c virus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1012180B1 (en) * 1997-08-11 2004-12-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
US6211338B1 (en) * 1997-11-28 2001-04-03 Schering Corporation Single-chain recombinant complexes of hepatitis C virus NS3 protease and NS4A cofactor peptide
AU772386B2 (en) * 1999-05-04 2004-04-29 Boehringer Ingelheim (Canada) Ltd. Surrogate cell-based system and method for assaying the activity of hepatitis C virus NS3 protease

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683864A (en) * 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
EP0450931A1 (en) * 1990-04-04 1991-10-09 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
WO1993009253A1 (en) * 1991-11-07 1993-05-13 Baxter Diagnostics Inc. Epitope mapping ot the c33c region of hcv
WO1995025122A1 (en) * 1994-03-17 1995-09-21 The Scripps Research Institute Peptides for inducing cytotoxic t lymphocyte responses to hepatitis c virus
EP0696640A2 (en) * 1994-08-12 1996-02-14 Boehringer Mannheim Gmbh Recombinant antigen from the NS3 region of hepatitis C virus
WO1999038880A1 (en) * 1998-01-30 1999-08-05 The General Hospital Corporation Genetic immunization with nonstructural proteins of hepatitis c virus

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHIEN DAVID Y ET AL: "Use of a novel hepatitis C virus (HCV) major-epitope chimeric polypeptide for diagnosis of HCV infection", JOURNAL OF CLINICAL MICROBIOLOGY, WASHINGTON, DC, US, vol. 37, no. 5, May 1999 (1999-05-01), pages 1393 - 1397, XP002155465, ISSN: 0095-1137 *
CHO J H ET AL: "Enhanced cellular immunity to hepatitis C virus nonstructural proteins by codelivery of granulocyte macrophage-colony stimulating factor gene in intramuscular DNA immunization", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 17, no. 9-10, 5 March 1999 (1999-03-05), pages 1136 - 1144, XP004158236, ISSN: 0264-410X *
CLARKE B: "Molecular virology of hepatitis C virus", JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, READING, GB, vol. 78, no. 10, 1997, pages 2397 - 2410, XP002172331, ISSN: 0022-1317 *
DIEPOLDER H ET AL: "Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection", J VIROL., vol. 71, no. 8, August 1997 (1997-08-01), pages 6011 - 6019, XP002179125 *

Also Published As

Publication number Publication date
CN1425027A (en) 2003-06-18
WO2001038360A2 (en) 2001-05-31
ATE376558T1 (en) 2007-11-15
EP1233982B1 (en) 2007-10-24
CN101684146A (en) 2010-03-31
CA2390082A1 (en) 2001-05-31
KR100788812B1 (en) 2007-12-27
KR20020065537A (en) 2002-08-13
DE60036881D1 (en) 2007-12-06
DE60036881T2 (en) 2008-07-10
JP2003516732A (en) 2003-05-20
WO2001038360A9 (en) 2002-12-12
EP1233982A2 (en) 2002-08-28
CA2390082C (en) 2010-06-29
AU2574601A (en) 2001-06-04

Similar Documents

Publication Publication Date Title
AU2574601A (en) Novel hcv non-structural polypeptide
DE69841690D1 (en) Chimeric vaccines against flaviviruses
CA2110058A1 (en) Hepatitis c virus (hcv) polypeptides
WO2004111082A3 (en) Compound containing polyprotein ns3/ns4 and hcv polypeptide ns5b, expression vectors comprising corresponding nucleic sequences and the therapeutic application thereof
DE69518642D1 (en) PEPTIDES FOR INDUCTION OF IMMUNE RESPONSE BY CYTOTOXIC T LYMPHOCYTES AGAINST THE VIRUS OF HEPATITIS C
WO2001030812A3 (en) Activation of hcv-specific t cells
CA2032381A1 (en) Viral agent
GR3006171T3 (en)
WO2001085932A3 (en) Immunogenic polypeptides encoded by mage minigenes and uses thereof
AU2002220460A1 (en) The polypeptide fragments of hepatitis e virus, the vaccine composition comprising said fragments and the diagnostic kits
HUT73384A (en) Methods of typing hepatitis c virus and reagents for use therein
WO1996012807A3 (en) Hepatitis e virus antigens and uses therefor
WO1995032290A3 (en) Non-a/non-b/non-c/non-d/non-e hepatitis agents and molecular cloning thereof
WO1999063941A3 (en) Novel hepatitis c virus peptides and uses thereof
GB9810756D0 (en) Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
AU5460900A (en) Infectious cdna clone of gb virus b and uses thereof
AU8156594A (en) Non-A non-B sequences
EP0516859A4 (en)
WO2004039950A3 (en) Activation of hcv-specific cells
AU7917200A (en) Hybrid or chimeric polynucleotides, proteins, and compositions comprising hepatitis b virus sequences
EP1010759A4 (en) Non-b non-c non-g hepatitis virus gene, polynucleotide, polypeptide, virion, method for separating virion, and method for detecting virus
WO2001068818A3 (en) Hcv ns2/3 fragments and uses thereof
WO2000001718A3 (en) Ns4a-ns3 catalytic domain of hepatitis c
AU5924396A (en) Compositions and methods for the diagnosis of, and vaccinati on against, hepatitis c virus (hcv)
EP0628572A3 (en) DNA originating in non-A non-B hepatitis virus gene and constituting polypeptide.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2390082

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 540123

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1020027006693

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2000989206

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 008185778

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020027006693

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000989206

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWG Wipo information: grant in national office

Ref document number: 2000989206

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)